Stroke occurs infrequently in large cohort study of patients hospitalized with COVID-19 Source:
Fanning J, et al. Stroke complicating critically ill patients with SARS-CoV-2: Analysis of the COVID-19 Critical Care Consortium (CCCC) international, multicenter observational study. Presented at: American Academy of Neurology Annual Meeting; April 17-22, 2021 (virtual meeting). Disclosures: Healio Neurology could not confirm relevant financial disclosures at the time of publication. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Date Time
Mayo study differentiates what blood-based proteins indicate about brain cell loss
Two proteins that can be measured in the blood – plasma total tau and neurofilament light – are associated with brain cell loss that causes memory and thinking problems. Neurofilament light was more strongly related to worse cognition and neurodegeneration, compared to total tau, according to a preliminary Mayo Clinic study that will be presented in the Emerging Science program at the 2021 virtual American Academy of Neurology Annual Meeting.
Brain cell loss, or neurodegeneration, is a common characteristic of many disorders, including Alzheimer’s disease, vascular dementia and Lewy body dementia. However, the causes and location of neurodegeneration in the brain vary depending on the disease.
Share this article
Share this article
MINNEAPOLIS, April 16, 2021 /PRNewswire/ A preliminary study suggests that Black people who have autoimmune neurologic diseases, multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), may respond differently than white people to a common therapy meant to modulate the immune system. The research will be presented at the American Academy of Neurology s 73rd Annual Meeting being held virtually April 17 to 22, 2021.
The people in this study were given anti-CD20 infusion therapies, which are often used to treat autoimmune diseases such as MS and neuromyelitis optica spectrum disorder, which is a relapsing inflammatory disorder of the optic nerve, spinal cord and brain. The goal of this treatment, called B-cell depletion therapy, is to destroy B-cells in blood circulation. B-cells are partly responsible for the abnormal autoimmune responses in people with MS and NMOSD.
Study: Black People May Respond Differently to Common MS Therapy than White People mesabitribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mesabitribune.com Daily Mail and Mail on Sunday newspapers.
E-Mail
MINNEAPOLIS - A large, year-long study has found that among people with COVID-19 who were hospitalized in an intensive care unit (ICU), 2% experienced a stroke after they were admitted to the ICU. The preliminary study released today, April 15, 2021, will be presented at the American Academy of Neurology s 73rd Annual Meeting being held virtually April 17 to 22, 2021. The study also found that hemorrhagic stroke, a bleeding stroke, was associated with a higher risk of death among people in the ICU, but ischemic stroke, a stroke caused by a blood clot blocking an artery, was not. Stroke has been a known serious complication of COVID-19 with some studies reporting a higher-than-expected occurrence, especially in young people, said study author Jonathon Fanning, M.B.B.S., Ph.D., of the University of Queensland in Brisbane, Australia, and a member of the American Academy of Neurology. However, among the sickest of patients, those admitted to an ICU, our research found that